Navigation Links
Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
Date:12/20/2013

LONDON, Dec. 20, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013.

Dear Fellow Shareholders,

As the executive management team of Lightlake Therapeutics Inc. looks ahead to 2014, we are encouraged by our hard work and progress in 2013 and are eager for the opportunities and advancements that 2014 should bring to our company. This has been a fruitful year for the Company as we have achieved a number of milestones, both operationally and clinically.  We continue to work diligently to advance our clinical pipeline and secure our patent portfolio as we focus on bringing an intranasal naloxone treatment to market to reverse opioid overdoses.

Since our last update in April 2013, we would like to highlight a few of our accomplishments.  We recently completed a two-week joint clinical study with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for opioid overdose.  We received the initial data from this study and it has shown that our naloxone nasal spray can potentially be delivered into the blood stream at least as quickly as the injection process currently used by hospitals, first responders, and others treating opioid overdoses.

The data received from this study will also allow us to apply our novel method of naloxone delivery into a wider range of various addictions that are currently affecting millions of people on a daily basis.  While opioid overdose is a significant, near-term opportunity that can potentially be treated with an intranasal naloxone application, there are a number of other markets that our application could potentially be app
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
2. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
3. Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
4. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
5. BiOptix Continues Support of Antibody Engineering & Therapeutics Research
6. NKT Therapeutics Identifies Novel anti-iNKT Antibodies for Depleting or Activating iNKT Cells
7. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
8. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
9. Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
10. Scientists develop way to successfully give nanoparticle therapeutics orally
11. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/22/2014)... , Sept. 22, 2014  WIRB-Copernicus Group ... ethical review services for clinical research, announced today ... (WIRB) has been reaccredited by the Association for ... which endeavors to improve safeguards for clinical research ... Donald A. Deieso , Ph.D., commented, "It is ...
(Date:9/21/2014)... University of Basel in Switzerland have succeeded in ... molecule for the first time. These extremely weak ... molecular properties and may also contribute to the ... results were published in the scientific journal ... the interaction between matter and light, is probably ...
(Date:9/20/2014)... 2014 MediVet America and ... groundbreaking surgery at the specialized Wolvega Horse Clinic. , ... flexor tendon was ruptured 90% and her deep digital ... a death sentence for a horse. , The clinic ... treatments . This revolutionary regenerative option for ruptured ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Uncovering the forbidden side of molecules 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... and STATE COLLEGE, Pennsylvania, May 9, 2012 ... and SoftGenetics announced today that the two firms ... provide users of 454 Sequencing Systems the broad ... by SoftGenetics NextGENe® software. NextGENe® software ...
... 2012 Phalanx Biotech Group, a global genomic ... of manufacturing and testing for a proprietary targeted ... postnatal detection of microdeletions and microduplications related to ... intellectual delay disorders. Cyto OneArray ® ...
... Nev., May 8, 2012 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, is scheduled to ... http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Eleventh Annual JMP Securities Research ... Francisco, CA Goldman Sachs 33rd Annual Global ...
Cached Biology Technology:Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 2Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 3Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray 2
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... (SACRAMENTO, Calif.) Mothers of children with autism are significantly ... during their pregnancies than the mothers of children who ... UC Davis MIND Institute has found. , Low iron ... autism in the child if the mother was 35 ... or if she suffered from metabolic conditions such as ...
(Date:9/21/2014)... of California, San Diego, have developed a program that ... activity of genes based on sequences of DNA. They ... to human embryonic cells in a paper published in ... of our cells have the same blueprint, the same ... lead author of the report. "Skin cells protect, nerve ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
... part of the skeletal support for the membrane in ... Joanny from the Physico Chemistry Curie Unit at the ... a well-defined layer beneath the cell outer membrane forms ... motor proteins within the cellular system. These findings, which ...
... NEW YORK , June 10, 2013   EyeLock Inc. ... the company has joined the Fast IDentity Online Alliance ... and more secure digital presence for consumers.  ... NXP, Nok Nok Labs and Validity, among others, ...
... that may be able to stop the spread of ... laboratory experiments conducted at Johannes Gutenberg University Mainz (JGU). ... order to evaluate their therapeutic potential. "The active substances ... killing off tumor cells that are resistant to more ...
Cached Biology News:Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords 2Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords 3Substances from African medicinal plants could help stop tumor growth 2
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
... cost effective cell culture services for the ... Quality at a reasonable price is our ... or commercial product, we strive toward customer ... roller bottles, hollow fiber, and bioreactor technologies, ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... for hunting and analyzing the rare ... EST sequencing projects, microarrays, functional screenings ... well suited for the normalization of ... though, is specially developed for normalization ...
Biology Products: